INTRODUCTION
Cytochrome P450 oxidoreductase deficiency (PORD) (OMIM: 613571 and OMIM: 201750) is a form of congenital adrenal hyperplasia. [1] [2] [3] [4] It was first described in 1985 in a patient with genital ambiguity and an abnormal urinary steroid profile, suggesting a 17,20 lyase and 21-hydroxylase, and was named P450 oxidoreductase. 5 Although disruption of the POR gene in mice causes gross disorders of embryogenesis and embryonic lethality, 6, 7 in 2004 Fluck et al reported POR mutations in three children with ambiguous genitalia and skeletal malformations [Antley-Bixler syndrome (ABS)] and in a phenotypically normal adult woman with primary amenorrhea and polycystic ovaries, leading to the characterization of PORD. 1 Skeletal malformation in many ABS patients with ambiguous genitalia and defective steroid metabolism have been linked to PORD, 8 which is today listed as a separate metabolic disorder characterized by disruption of steroid biosynthesis in the adrenal gland and gonads. [8] [9] [10] [11] To date, more than 50 mutations have been reported, 12, 13 indicating that this disorder might not be uncommon.
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CASE PRESENTATION
A 36-year old-man, who was operated on for cryptorchidism at the age of 8 years, was referred to our Outpatient Clinic of Reproductive Endocrinology in 2004 for investigation of infertility. There was a negative family history of Congenital Adrenal Hyperplasia (CAH) and other cases of ambiguous genitalia/infertility within the family. The patient was not receiving any medication. He was euthyroid, with no sign of gynecomastia or BMI 27.4 kg/m 2 (height: 180 cm weight: 89 Kg). Clinical examination revealed a penis of 4-5 cm, testicular volume 2-3 ml, as well as hypospadias, hypertrophic foreskin and scrotum bifida ( Figure 1 ). Scrotal ultrasonography confirmed a testicular volume of 2 ml. Two spermiograms were performed (volume 1.5ml and pH 7.2), revealing azoospermia.
Mild hypertension was also found. Hormonal and electrolytic determinations as well as semen analysis and karyotyping were the preliminary examinations conducted. No skeletal malformations were noted, while X-rays of the upper and lower extremities were normal. Based on the study by Krone et al, 16 the malformation scoring system for PORD patients, including midface hypoplasia, craniosynostosis, hand and feet malformations, large joint synostosis, femoral bowing, and the presence of nonskeletal malformations, was 0. Bone densitometry with DXA revealed mild spinal cord osteopenia (z score: -1.5).
Although the patient was concerned about his fertility, after a thorough discussion he was put on testosterone treatment (IM testosterone undecanoate) in order to achieve a satisfactory sexual life. Later on, an attempt to initiate spermatogenesis was performed by hCG and FSH administration. After 18 months of treatment, testicular biopsy on both testes revealed no foci of spermatogenesis and the patient was returned to testosterone treatment.
GENOTYPING
Informed consent was obtained from the patient. Genomic DNA was extracted from peripheral blood leukocytes, followed by PCR of the coding regions of 17-hydroxylase/17,20 lyase (P450c17) and of P450 oxidoreductase (POR) genes. PCR products were subjected to sequence analysis.
The primers and the PCR reactions for the 17-hydroxylase/17,20 lyase 17 and the P450 oxidoreductase 18 genes have been previously described. The PCR fragments were subjected to DNA sequence analysis (Macrogen Europe, Amsterdam, The Netherlands).
In order to identify the potential impact of the identified mutations on protein function, we used three free access applications: MutationTaster (http://www. mutationtaster.org/), 19 SIFT (http://sift.bii.a-star.edu. sg) 20 and Hansa (http://hansa.cdfd.org.in:8080/index. php?target=search). 21, 22 
RESULTS
Karyotyping showed a normal male 46,XY, while semen analysis indicated azoospermia. Mild hypertension was confirmed. Biochemical tests were normal (K 4.6 and Na 144), whereas the hormonal profile revealed: low levels of androgens (Testo 0.4 ng/ml high levels of Gonadotropins (LH 26 mIU/ml (1.8-12.0 mIU/L), FSH 54 mIU/ml (1.3-19.3 mIU/mL) as well as high 17-OH-progesterone levels (17-OH-Pr 11,7ng/ml range:(0.4-3.3 ng/ml), Serum E2 concentration was 23.9 pg/ml (20-60 pg/ml). After ACTH stimulation, mild adrenal insufficiency was observed. Both hCG and ACTH stimulation substantially increased 17-hydroxyprogesterone levels (12.05ng/ ml and 35 ng/ml, respectively) with no increase in and androstenedione 0.7 ng/ml). Baseline cortisol was Consequently, the diagnosis was congenital adrenal hyperplasia with apparent combined P450c17 and P450c21 deficiency due to mutations in the POR gene.
Sequencing of POR 15 exons revealed: one deletion in exon 12 (chr7:75615089_75615091delGTC, c.1591_1593delGTC, cDNA.1696_1698delGTC, g.86572_86574delGTC del531Valine) and one novel missense mutation in exon 7 (G858C, A259G) as well as two known polymorphisms: rs1057868 (C/T A503V) and rs1057870 (G/A S572S) in exons 12 and 13, respectively (Figure 2 ).
Mutation Taster identified the del531V as "disease causing", with a probability of 0.999999999963763, thus predicting that the amino acid sequence, the protein features as well as the splice sites would be affected. It should be mentioned that 531V is a highly conserved amino acid among species and the only acceptable alternative could be Isoleucine. The A259G variant was also categorized as "disease causing", with a probability of 1, pointing to affected protein features and splice sites. The A259G variant was also No nucleotide changes were detected in the 8 exons of P450c17.
The mutation numbering was carried out by referring to the appropriate National Center for Biotechnology Information (Bethesda, MD) reference sequences [P450 oxidoreductase, NM_000941.2 and NP_000932 (protein).
It was not possible to obtain parental DNA in order to compare our findings and provide information about the inheritance.
DISCUSSION
It is very unusual to come across a case of ambiguous genitalia while evaluating infertility in an adult male. Despite the fact that the patient in question had previously been evaluated by several doctors, attention had been focused on hormonal and semen determinations without a careful physical examination. The patient's insistence on preserving fertility had apparently impeded an accurate diagnosis. Although it is extremely rare for ambiguous genitalia to be discovered in an adult male seeking fertility, physical examination of the external genitalia should never be omitted.
The diagnosis was based on the fact that plasma increased 17-OH-Pr and decreased androgens both at baseline as well as after ACTH and hCG stimulation. Urinary steroid determination by gas chromatographymass spectrometry was not performed, initially because our hospital lacked the facilities and then due to our patient's departure abroad.
Since the initial description of cytochrome P450 oxidoreductase deficiency, 5 more than 50 mutations have been reported, 12, 13 suggesting that this disorder might be quite common. 4, 14, 15 The fact that a patient with two apparently null mutations has never been described implies that absence of residual POR activity is incompatible with life. 8, 13, 23 POR mutations can lead to an apparent combined 17-hydroxylase/21-hydroxylase deficiency (OMIM 201750) and a broad spectrum of clinical characteristics, ranging from severe neonatal skeletal malformations with genital ambiguity [known as Antley Bixler syndrome (ABS); OMIM 207410] to phenotypically minor polycystic ovary syndrome-like features. 1, 2, 8, 10, [24] [25] [26] Milder POR mutations might not be accompanied by ABS, and the steroidogenic defect may present as hypogonadism and/or infertility. 1, 8, 14, 27 Our patient was diagnosed with congenital adrenal hyperplasia with apparent combined P450c17 and P450c21 deficiency due to mutations in the POR gene. The genotyping revealed the del531Valine, the missense mutation A259G as well as two polymorphisms: rs1057868 (A503V) and rs1057870 (S572S). However, the unavailability of parental DNA means that there is, unfortunately, no information as to their allelic distribution.
The deletion del531Valine as well as the A259G change have not been previously reported. In silico analysis defined these aminoacidic alterations as disease-causative, but the confirmative data for their pathogenicity would be provided by in vitro assays that would measure the variants' enzymatic activity while determining the variants' allelic localization. Our lack of the required laboratory facilities, resulting in the non-availability of in vitro data, is a limitation of the study.
Regarding the A503V variant, by far the most common POR polymorphism with an overall incidence of 27.9%, 15, 28 there is a discrepancy between the reported measurements of its activity depending on the assay used. In the classic, non-physiologic assay based on cytochrome c, the ability of A503V to reduce cytochrome c and its ability to oxidize NADPH was 67% and 56% of WT, respectively. 28 Measurements of the activity of A503V to support catalysis by steroidogenic enzymes varied: A503V had 68% of WT ability to support the 17-hydroxylase activity of human P450c17 and 58% of WT ability to support the 17,20 lyase activity of P450c17. 8, 28 By contrast, A503V had 80% of WT activity to support the 21-hydroxylation of progesterone by human P450c21, and 95% of WT ability to support the 21-hydroxylation of 17-OH-progesterone. 29 Thus, although A503V is evidently not a modifier gene, since it only moderately impaired the metabolism of testosterone, 15, 30 it could be assigned a synergistic role 12 in causing disease.
